DOIS_STRLV
ID DOIS_STRLV Reviewed; 384 AA.
AC Q2MF70;
DT 02-MAY-2006, integrated into UniProtKB/Swiss-Prot.
DT 21-FEB-2006, sequence version 1.
DT 03-AUG-2022, entry version 38.
DE RecName: Full=2-deoxy-scyllo-inosose synthase;
DE Short=DOI synthase;
DE Short=DOIS;
DE EC=4.2.3.124;
GN Name=livC;
OS Streptomyces lividus.
OC Bacteria; Actinobacteria; Streptomycetales; Streptomycetaceae;
OC Streptomyces.
OX NCBI_TaxID=282216;
RN [1]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC STRAIN=CBS 844.73;
RA Aboshanab K.M.A., Schmidt-Beissner H., Wehmeier U.F., Piepersberg W.,
RA Welzel K., Vente A.;
RT "Analysis and comparison of biosynthetic gene clusters for the 2-deoxy-
RT inosamine containing aminoglycoside antibiotics ribostamycin, neomycin,
RT lividomycin, paromomycin and butirosin.";
RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
CC -!- FUNCTION: Catalyzes the intramolecular carbocycle formation from D-
CC glucose-6-phosphate to 2-deoxy-scyllo-inosose (DOI). {ECO:0000250}.
CC -!- CATALYTIC ACTIVITY:
CC Reaction=D-glucose 6-phosphate = 2-deoxy-L-scyllo-inosose + phosphate;
CC Xref=Rhea:RHEA:33071, ChEBI:CHEBI:43474, ChEBI:CHEBI:61548,
CC ChEBI:CHEBI:64796; EC=4.2.3.124;
CC -!- COFACTOR:
CC Name=NAD(+); Xref=ChEBI:CHEBI:57540;
CC Evidence={ECO:0000250|UniProtKB:Q9S5E2};
CC -!- COFACTOR:
CC Name=Co(2+); Xref=ChEBI:CHEBI:48828;
CC Evidence={ECO:0000250|UniProtKB:Q9S5E2};
CC Note=Binds 1 Co(2+) ion per subunit. {ECO:0000250|UniProtKB:Q9S5E2};
CC -!- PATHWAY: Metabolic intermediate biosynthesis; 2-deoxystreptamine
CC biosynthesis; 2-deoxystreptamine from D-glucose 6-phosphate: step 1/4.
CC -!- PATHWAY: Antibiotic biosynthesis; lividomycin biosynthesis.
CC -!- SIMILARITY: Belongs to the sugar phosphate cyclases superfamily. DOI
CC synthase family. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AJ748832; CAG38697.1; -; Genomic_DNA.
DR AlphaFoldDB; Q2MF70; -.
DR SMR; Q2MF70; -.
DR UniPathway; UPA00907; UER00921.
DR UniPathway; UPA00968; -.
DR GO; GO:0016838; F:carbon-oxygen lyase activity, acting on phosphates; IEA:InterPro.
DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR GO; GO:0017000; P:antibiotic biosynthetic process; IEA:UniProtKB-KW.
DR GO; GO:0009073; P:aromatic amino acid family biosynthetic process; IEA:InterPro.
DR InterPro; IPR030963; DHQ_synth_fam.
DR InterPro; IPR030960; DHQS/DOIS.
DR Pfam; PF01761; DHQ_synthase; 1.
DR PIRSF; PIRSF001455; DHQ_synth; 1.
PE 3: Inferred from homology;
KW Antibiotic biosynthesis; Cobalt; Lyase; Metal-binding; NAD.
FT CHAIN 1..384
FT /note="2-deoxy-scyllo-inosose synthase"
FT /id="PRO_0000234038"
FT ACT_SITE 142
FT /evidence="ECO:0000250|UniProtKB:Q9S5E2"
FT ACT_SITE 244
FT /evidence="ECO:0000250|UniProtKB:Q9S5E2"
FT BINDING 42
FT /ligand="NAD(+)"
FT /ligand_id="ChEBI:CHEBI:57540"
FT /evidence="ECO:0000250|UniProtKB:Q9S5E2"
FT BINDING 73..76
FT /ligand="NAD(+)"
FT /ligand_id="ChEBI:CHEBI:57540"
FT /evidence="ECO:0000250|UniProtKB:Q9S5E2"
FT BINDING 105..109
FT /ligand="NAD(+)"
FT /ligand_id="ChEBI:CHEBI:57540"
FT /evidence="ECO:0000250|UniProtKB:Q9S5E2"
FT BINDING 129..130
FT /ligand="NAD(+)"
FT /ligand_id="ChEBI:CHEBI:57540"
FT /evidence="ECO:0000250|UniProtKB:Q9S5E2"
FT BINDING 140..142
FT /ligand="NAD(+)"
FT /ligand_id="ChEBI:CHEBI:57540"
FT /evidence="ECO:0000250|UniProtKB:Q9S5E2"
FT BINDING 151..152
FT /ligand="NAD(+)"
FT /ligand_id="ChEBI:CHEBI:57540"
FT /evidence="ECO:0000250|UniProtKB:Q9S5E2"
FT BINDING 184
FT /ligand="Co(2+)"
FT /ligand_id="ChEBI:CHEBI:48828"
FT /evidence="ECO:0000250|UniProtKB:Q9S5E2"
FT BINDING 247
FT /ligand="Co(2+)"
FT /ligand_id="ChEBI:CHEBI:48828"
FT /evidence="ECO:0000250|UniProtKB:Q9S5E2"
FT BINDING 263
FT /ligand="Co(2+)"
FT /ligand_id="ChEBI:CHEBI:48828"
FT /evidence="ECO:0000250|UniProtKB:Q9S5E2"
SQ SEQUENCE 384 AA; 40173 MW; 44E6BAAB42E7351F CRC64;
MHVTAITMED ANFPYRLGTD CAEELVARLG VRAASRYLVV CDTTVAALYG HDLVARLEKD
AGPAVLLTHQ VGEVHKDVTT VGALAEQALG AGADRRSVVV ALGGGITGNI AGLLAALLFR
GITLVHVPTT VVAMLDSVLS LKQAVNASFG KNLVGTFYQP AEVLADTAML RTLPEREVRS
GMGEVVKNAL AVRPAMADRL AGLLRPDARY DDDALRWIIA ESVAAKADVT GADKHERGDG
LVLEYGHTAG HAIEHAARGA VAHGAGVAVG MVIAAEVSHR LGHASASFVA RHRELISKAG
LEDTVPACVR TDDVKNWLTY DNKRGYLDCA ADTTPMVLLA GPGRPLRTGG MPLVPVPLAV
LNETVDALAA PGRAGTDHRT AVPV